Saturday - June 03, 2023

Treatment-Resistant Hypertension Market to Grow Substantially During the Forecast Period (2022-2032) – DelveInsight | Key Companies – CinCor Pharma, Ionis Pharma, Idorsia, Janssen, Vifor Pharma

Delveinsight Business Research LLPTreatment-resistant Hypertension market size in the seven major markets was USD 13 billion in 2021. As per DelveInsight, the Treatment-Resistant Hypertension Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases, the launch of new therapies, and the active participation of the pharma and biotech companies such as Quantum Genomics, Idorsia Pharmaceuticals, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, among others in the therapeutic domain.DelveInsight's "Treatment-Resistant Hypertension Market Insights, ...

Excessive Daytime Sleepiness Market to Observe Stupendous Growth During the Forecast Period (2022-2032) | Key Companies – Takeda, Theranexus, XW Pharma, Avadel, Axsome Therapeutics, Benevolent AI Bio

Delveinsight Business Research LLPThe Excessive Daytime Sleepiness therapeutic market in the 7MM was USD 4,946 million in 2021. As per DelveInsight, the Excessive Daytime Sleepiness Market is anticipated to evolve immensely in the coming years owing to the expected approval of emerging therapies, expansion in the label of current therapies, and the increasing patient population of EDS in the 7MM.DelveInsight's "Excessive Daytime Sleepiness Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and ...

Treatment Resistant Depression Market to Grow Rapidly During the Forecast Period (2022-2032) – DelveInsight | Key Companies – AbbVie, ACADIA, Alkermes, Beckley Psytech, Celon Pharma, Navitor, Pherin

Delveinsight Business Research LLPAs per DelveInsight, the total Treatment Resistant Depression (TRD) market size in the 7MM was found to be ~USD 3,100 million in 2022 and is projected to increase during the forecast period (2023–2032). The Treatment Resistant Depression Market is anticipated to evolve immensely in the coming years owing to the growth in healthcare spending across the world, the rise in the number of cases, and the launch of new therapies in the market.DelveInsight's "Treatment Resistant Depression Market ...

Marcus Romanzo’s Book Of Life Long Short Stories is out now

The book features a collection of short stories showcasing his passion for storytelling and free-thinking mindset.Marcus Romanzo, a 74-year-old author, has announced the publication of his debut book, “Marcus Romanzo's Book Of Life Long Short Stories.” The book features an assemblage of excellent short stories from the Fiction and Non-Fiction genres. The book proves Marcus’s keen eye for detail and his passion for storytelling. Marcus considers himself a free thinker, and his stories reflect this mindset. He believes that everyone is ...

Diamond Bar Dental Studio Sets New Standard for Company Culture in Dentistry

Diamond Bar Dental Studio revolutionizes the dental industry with a culture of collaboration, professional development, and patient-centered care.Diamond Bar Dental Studio, a leading dental practice in the community since 1995, is proud to announce that they have set a new benchmark for company culture within the field of dentistry. By fostering an environment of collaboration, professional development, and work-life balance, Diamond Bar Dental Studio has created a practice where patients and team members thrive on creating a symphony generating positive ...

Prostate Cancer Market to Advance at Moderate CAGR During the Forecast Period (2022-2032) – Estimates DelveInsight | Novartis, ESSA Pharma, Roche, Merck, AstraZeneca, Orion, Advantagene, Astellas

Delveinsight Business Research LLPAs per DelveInsight, the Prostate Cancer Market is anticipated to evolve immensely in the coming years owing to the increasing number of cases of prostate cancer, the rising number of risk factors associated with prostate cancer, growing awareness regarding prostate cancer among men, and the launch of new therapies in the market.Moreover, the increasing research and development activities, increasing technological advancements such as the incorporation of artificial intelligence (AI) in prostate cancer diagnosis, and government and non-government ...

CRISPR Therapies Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Intellia, CRISPR Therapeutics, Caribou, Emendo, Sarepta, Editas, AstraZeneca

DelveInsight Business Research LLPAs per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the CRISPR therapeutics market. Several of the CRISPR therapies are in the advanced stages of clinical development and are expected to launch in the coming years.“CRISPR Therapies Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the CRISPR Therapies Market.  The CRISPR Therapies Pipeline report embraces in-depth commercial ...

Crohn’s Disease Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Janssen, RedHill Biopharma, Gilead, Galapagos, Eilly Lilly, Takeda

Delveinsight Business Research LLPAs per DelveInsight’s assessment, globally, about 90+ key pharma and biotech companies are working on 90+ pipeline drugs in the Crohn's Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.“Crohn's Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and ...

Complicated Intra-Abdominal Infections Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MerLion, AiCuris, Novartis, Allecra, AbbVie, Shionogi

Delveinsight Business Research LLPAs per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Complicated Intra-Abdominal Infections therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.“Complicated Intra-Abdominal Infections Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development ...

Acurx Pharmaceuticals Completes $4.0 Million Equity Offering That Accelerates Mission To Bring A Front-Line C. difficile Treatment To Market ($ACXP)

Acurx Pharmaceuticals (NasdaqCM: ACXP) announced completing a stock purchase agreement with a single institutional investor in May 2023, offering a mix of shares and warrants to provide ACXP with $4.0 million before fees and offering expenses at $3 per share. Ironically, shares traded lower on the deal's announcement. But that's not necessarily bad news. The weakness exposes opportunity, which, in this case, could be too good to ignore.  In other words, investors should not be misled by the recently out-of-character move. ...